Study of PRRT treatment for pheochromocytoma and paraganglioma
Part of Cancer clinical trials.
This study looks back at the experiences of people who have been treated with a special type of radiation therapy, called PRRT, for rare tumors like pheochromocytoma or paraganglioma. It aims to learn how well the treatment worked and how long its effects lasted, to improve future care for others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pheochromocytoma or paraganglioma (rare tumors of the adrenal glands or nerve tissue).
- Your tumor is either advanced (spread to other parts) or cannot be removed with surgery.
- You have received at least one cycle of treatment called PRRT (peptide receptor radionuclide therapy).
- Your doctors have access to your medical records, including details of your treatment and follow-up scans or tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This study looks at people who have been newly diagnosed with pheochromocytoma/paraganglioma (PPGL), those with a past history of PPGL, or those with genetic risk for it. It may help doctors better evaluate and understand PPGL using specific tests.
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
This trial tests if a special ultrasound can help doctors see how well treatment is working for a type of slow-growing gut or pancreas cancer (GEP-NET). It may help guide your care if you are starting a therapy called PRRT (peptide receptor radionuclide therapy).
This trial tests whether taking a somatostatin analogue (a drug that slows tumor growth) after PRRT (a type of radiation therapy targeted at tumor cells) is better than just watching and waiting. It is for people with advanced neuroendocrine tumors that are not causing hormone-related symptoms.
Hear when a new Pheochromocytomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.